Trium Capital LLP Inozyme Pharma, Inc. Transaction History
Trium Capital LLP
- $830 Million
- Q2 2025
A detailed history of Trium Capital LLP transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Trium Capital LLP holds 3,173,454 shares of INZY stock, worth $12.7 Million. This represents 1.53% of its overall portfolio holdings.
Number of Shares
3,173,454Holding current value
$12.7 Million% of portfolio
1.53%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
88Shares Held
51.9MCall Options Held
162KPut Options Held
0-
Beryl Capital Management LLC Redondo Beach, CA6.32MShares$25.3 Million3.83% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million16.98% of portfolio
-
Glazer Capital, LLC New York, NY4.33MShares$17.3 Million0.62% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million1.16% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...